RankingsPricing
  1. US-listed companies
  2. NEUROCRINE BIOSCIENCES INC
  3. Financials
  4. Cash from investing

NEUROCRINE BIOSCIENCES INCNBIX

Market cap
$15.2B
P/E ratio
SummaryFinancials
Period EndCash from investing (Million USD)YoY (%)
Dec 31, 2024-127-72.85%
Dec 31, 2023-467+163.75%
Dec 31, 2022-177+36.02%
Dec 31, 2021-130-3275.61%
Dec 31, 20204-101.94%
Dec 31, 2019-211-13.11%
Dec 31, 2018-243-3.17%
Dec 31, 2017-251-322.28%
Dec 31, 2016113-157.64%
Dec 31, 2015-196+85.84%
Dec 31, 2014-105-2073.15%
Dec 31, 20135-115.36%
Dec 31, 2012-35+879.46%
Dec 31, 2011-4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)